H U Bryant

No ORCID on file · 1 paper in corpus · active 1998

Study types

  • review 1

Condition tags

  • endometriosis 1
review 1998
Reproductive toxicology (Elmsford, N.Y.) ·doi:10.1016/s0890-6238(98)00003-3

Raloxifene is a nonsteroidal, selective estrogen receptor modulator being developed by Eli Lilly and Company as a therapeutic agent for postmenopausal osteoporosis. In the ovariectomized (OVX) rat, raloxifene prevents the loss of bone at th…